WuXi Biologics News and Resources

Aadi Bioscience, Inc. has entered into a significant licensing agreement with WuXi Biologics and HANGZHOU DAC Biotechnology Co., Ltd., aimed at developing and commercialising a portfolio of next-generation antibody-drug conjugates (ADCs). This collaboration gives Aadi exclusive rights to three preclinical

WuXi Biologics has announced significant accomplishments at its state-of-the-art greenfield site in Dundalk, Ireland, marking a key milestone in its global biomanufacturing network. The facility has completed multiple successful 16,000-liter Process Performance Qualification (PPQ) runs, with two completed runs achieving

WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced plans to enhance its drug product (DP) capabilities at its Leverkusen, Germany facility. The company will add a new sterile filling line for prefilled syringes (PFS) using

WuXi Biologics (“WuXi Bio”) has announced the launch of its WuXia RidGS platform, aimed at improving the development of therapeutic proteins, particularly monoclonal antibodies (mAbs). This innovative platform employs a glutamine synthetase (GS)-knockout CHO expression system, which leverages zinc finger

WuXi Biologics has announced the successful scale-up of its proprietary WuXiUI™ platform to 2,000L GMP manufacturing, marking a significant milestone in biologics production. This achievement, which utilises the company’s ultra-intensified fed-batch bioprocessing technology, has resulted in a fourfold increase in

WuXi Biologics, a global contract research, development, and manufacturing organisation (CRDMO), has announced a partnership with MediGene to develop TCR-guided T cell engagers (TCR-TCEs) for the treatment of difficult-to-treat tumours. The collaboration, set for three years, aims to design and

WuXi Biologics (“WuXi Bio”) announced that four manufacturing facilities and the Suzhou Biosafety Testing Center in China have received Good Manufacturing Practice (GMP) certificates from the European Medicines Agency (EMA). The EMA issued GMP certificates following comprehensive inspections of WuXi

WuXi Biologics (2269.HK), a global Contract Research, Development, and Manufacturing Organization (CRDMO), has been named once again as a constituent of the FTSE4Good Index Series, marking its fourth consecutive year of inclusion. Launched by FTSE Russell, the FTSE4Good Index Series

WuXi Biologics, a contract research, development and manufacturing organisation (CRDMO), has successfully installed three new sets of 5,000L single-use bioreactors at its MFG20 drug substance manufacturing facility in Hangzhou, China. This move enhances the manufacturing capability at the site by

A bipartisan group of U.S. lawmakers has called for sanctions against Chinese biotech firm WuXi AppTec and its contract services affiliate WuXi Biologics. In a letter dated February 12, the lawmakers urged top Biden administration officials to review the global